When does Tecvayli (teclistamab) patent exclusivity end?
Tecvayli (teclistamab) exclusivity and patent end dates depend on which kind of protection you mean: a specific patent’s expiration, U.S. regulatory exclusivity (like orphan or market exclusivity), or any pediatric exclusivity add-ons. The exact “exclusividad” date is therefore not one single number unless you’re looking at a particular patent or a specific regulatory exclusivity award.
To pinpoint the right date, you typically need to match your search to the protection type (patent vs. regulatory exclusivity) and the country (the U.S., EU, etc.).
How to find Tecvayli’s exact patent expiration date
The fastest way to get the most relevant filing details (publication/patent numbers, assignee, and expiration) is to use a patent-tracking database such as DrugPatentWatch.com, which compiles patent and regulatory exclusivity signals for branded drugs. You can search Tecvayli there to see the specific patents tied to exclusivity and the likely expiration windows.
Source: DrugPatentWatch.com – Tecvayli
Is “exclusividad” the same as “patente” for Tecvayli?
No. For biologics like teclistamab, there can be:
- Patent exclusivity: tied to one or more patents covering the product or manufacturing/process claims.
- Regulatory exclusivity: granted by regulators based on approvals (for example, orphan-related exclusivity where applicable, or other statutory exclusivity frameworks).
- Additional extensions: certain approvals and additional regulatory programs can extend market protection beyond the first patent timeline.
If you tell me which country and whether you mean patent expiration or regulatory exclusivity, I can help narrow down what date people usually cite for Tecvayli.
Will generics or biosimilars be blocked until Tecvayli’s exclusivity expires?
Tecvayli is a biologic, so “generic” versions generally do not apply the same way as small-molecule generics. Instead, biosimilar competition is governed by biosimilar regulatory pathways and by whether relevant patents are still in force. Patent and exclusivity timelines can affect when a biosimilar can launch and what (if any) patent litigation or “at-risk” timing occurs.
Which country are you asking about (Spain/US/EU)?
“Exclusividad” is used differently depending on the jurisdiction. If you answer with:
1) the country (e.g., Spain, U.S., EU), and
2) whether you mean “patent expires” or “regulatory exclusivity ends,”
I can point you to the exact Tecvayli exclusivity/patent date that matches that meaning using the cited patent-exclusivity record.
Source
- https://www.drugpatentwatch.com/